BioAtla Inc. (BCAB)
BioAtla Statistics
Share Statistics
BioAtla has 58.4M shares outstanding. The number of shares has increased by 20.59% in one year.
| Shares Outstanding | 58.4M |
| Shares Change (YoY) | 20.59% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 49.68% |
| Shares Floating | 45.37M |
| Failed to Deliver (FTD) Shares | 29.97K |
| FTD / Avg. Volume | 3.52% |
Short Selling Information
The latest short interest is 5.06M, so 8.72% of the outstanding shares have been sold short.
| Short Interest | 5.06M |
| Short % of Shares Out | 8.72% |
| Short % of Float | 10.39% |
| Short Ratio (days to cover) | 2.97 |
Valuation Ratios
The PE ratio is -0.41 and the forward PE ratio is -0.37. BioAtla's PEG ratio is 0.01.
| PE Ratio | -0.41 |
| Forward PE | -0.37 |
| PS Ratio | 2.61 |
| Forward PS | 0.2 |
| PB Ratio | 2.01 |
| P/FCF Ratio | -0.4 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for BioAtla.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.52, with a Debt / Equity ratio of 0.06.
| Current Ratio | 3.52 |
| Quick Ratio | 3.52 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $180.33K |
| Profits Per Employee | $-1.14M |
| Employee Count | 61 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -92.63% in the last 52 weeks. The beta is 1.07, so BioAtla's price volatility has been higher than the market average.
| Beta | 1.07 |
| 52-Week Price Change | -92.63% |
| 50-Day Moving Average | 0.39 |
| 200-Day Moving Average | 1.27 |
| Relative Strength Index (RSI) | 32.21 |
| Average Volume (20 Days) | 852.34K |
Income Statement
In the last 12 months, BioAtla had revenue of 11M and earned -69.78M in profits. Earnings per share was -1.44.
| Revenue | 11M |
| Gross Profit | 11M |
| Operating Income | -73.94M |
| Net Income | -69.78M |
| EBITDA | -73.94M |
| EBIT | -73.94M |
| Earnings Per Share (EPS) | -1.44 |
Balance Sheet
The company has 49.05M in cash and 836K in debt, giving a net cash position of 48.21M.
| Cash & Cash Equivalents | 49.05M |
| Total Debt | 836K |
| Net Cash | 48.21M |
| Retained Earnings | -486.04M |
| Total Assets | 52.42M |
| Working Capital | 36.69M |
Cash Flow
In the last 12 months, operating cash flow was -71.94M and capital expenditures 0, giving a free cash flow of -71.94M.
| Operating Cash Flow | -71.94M |
| Capital Expenditures | 0 |
| Free Cash Flow | -71.94M |
| FCF Per Share | -1.48 |
Margins
Gross margin is 100%, with operating and profit margins of -672.21% and -634.33%.
| Gross Margin | 100% |
| Operating Margin | -672.21% |
| Pretax Margin | -634.33% |
| Profit Margin | -634.33% |
| EBITDA Margin | -672.21% |
| EBIT Margin | -672.21% |
| FCF Margin | -653.96% |
Dividends & Yields
BCAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BCAB is $3, which is 971.4% higher than the current price. The consensus rating is "Hold".
| Price Target | $3 |
| Price Target Difference | 971.4% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -16.32 |
| Piotroski F-Score | 2 |